Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline

MerckMerck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. The new building will span 145,000 square feet, offering new laboratory and collaborative working space to accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology and immunology.

"Our talented and passionate R&D teams based in Billerica have been highly engaged in advancing a number of pipeline compounds," said Luciano Rossetti, MD, Global Head of R&D for the biopharma business of Merck. "We continue to strengthen our innovation footprint in both the U.S. and Darmstadt, Germany where our global R&D headquarters are located, with the goal of delivering transformational value to patients around the world."

With this latest project, Merck will have invested more than $150 million in infrastructure to advance biopharmaceutical R&D in the state of Massachusetts in recent years, with more than 150 new jobs added to its growing U.S. R&D Hub in Billerica since 2011. The town of Billerica played a critical role in bringing this latest building expansion project to fruition, working collaboratively with Company officials to underscore the benefits of expanding the state-of-the-art R&D facility.

"Merck's continued investment in Massachusetts is a testament to the state’s global leadership in life sciences," said Travis McCready, President and CEO of the Massachusetts Life Sciences Center. "In working collaboratively with the town of Billerica, the company's campus expansion over the past decade has not only helped attract and retain top talent in the area, but more importantly, contributed to improving the lives of people with serious medical needs."

When construction is completed in 2021, the building will offer wet labs, office space and a cafeteria for the campus. Consistent with previous projects, the building will be constructed to the highest environmental and employee wellness standards by seeking LEED and WELL certifications. LEED® is a preeminent program for the design, construction and operation of high-performance green buildings. WELL is a building standard focused on enhancing people's health and wellness through built environments.

The healthcare business of Merck employs approximately 3,500 R&D professionals across four global R&D hubs: Darmstadt, Germany; Boston, U.S.; Tokyo, Japan; and Beijing, China. Merck invests approximately 20% of total sales in R&D discovery and development each year.

Merck's U.S. presence is comprised of three businesses - Healthcare, Life Science and Performance Materials - with nearly 10,000 employees working in R&D, manufacturing and corporate roles across almost 60 sites country-wide. Within the state of Massachusetts, more than 2,800 professionals work across 10 locations.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - Merck is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...